These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25952367)

  • 21. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II).
    Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Koike M; Sato K; Kono S; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 47(2):487-93. PubMed ID: 26401570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
    Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
    Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.
    Kavanagh S; Van Baelen B; Schäuble B
    J Alzheimers Dis; 2011; 27(3):521-30. PubMed ID: 21891871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study.
    Hager K; Baseman AS; Nye JS; Brashear HR; Han J; Sano M; Davis B; Richards HM
    Alzheimers Res Ther; 2016 Nov; 8(1):47. PubMed ID: 27846868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).
    Litvinenko IV; Odinak MM; Mogil'naya VI; Emelin AY
    Neurosci Behav Physiol; 2008 Nov; 38(9):937-45. PubMed ID: 18975103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Kurz AF; Erkinjuntti T; Small GW; Lilienfeld S; Damaraju CR
    Eur J Neurol; 2003 Nov; 10(6):633-40. PubMed ID: 14641507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
    Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
    Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
    Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.
    Tangwongchai S; Thavichachart N; Senanarong V; Poungvarin N; Phanthumchinda K; Praditsuwan R; Nidhinandana S; Chankrachang S
    Am J Alzheimers Dis Other Demen; 2008 Dec-2009 Jan; 23(6):593-601. PubMed ID: 18845693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the efficacy of a cognitive rehabilitation treatment on a group of Alzheimer's patients with moderate cognitive impairment: a pilot study.
    Salotti P; De Sanctis B; Clementi A; Fernandez Ferreira M; De Silvestris T
    Aging Clin Exp Res; 2013 Aug; 25(4):403-9. PubMed ID: 23760946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD).
    Giordano M; Dominguez LJ; Vitrano T; Curatolo M; Ferlisi A; Di Prima A; Belvedere M; Barbagallo M
    Arch Gerontol Geriatr; 2010; 51(3):245-9. PubMed ID: 19969381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two galantamine titration regimens in patients switched from donepezil.
    Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
    Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease.
    Park JJ; Choi SH; Kim S; Lee AY; Moon SY; Lee JH; Kwon JC; Park KW; Ku BD; Han HJ; Kim EJ; Shim YS
    Geriatr Gerontol Int; 2017 Oct; 17(10):1661-1666. PubMed ID: 27935239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-dependent cognitive and affective differences in Alzheimer's and Parkinson's diseases in relation to MRI findings.
    Tokuchi R; Hishikawa N; Sato K; Hatanaka N; Fukui Y; Takemoto M; Ohta Y; Yamashita T; Abe K
    J Neurol Sci; 2016 Jun; 365():3-8. PubMed ID: 27206864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional connectivity increase in the default-mode network of patients with Alzheimer's disease after long-term treatment with Galantamine.
    Blautzik J; Keeser D; Paolini M; Kirsch V; Berman A; Coates U; Reiser M; Teipel SJ; Meindl T
    Eur Neuropsychopharmacol; 2016 Mar; 26(3):602-13. PubMed ID: 26796681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of galantamine in patients with mild Alzheimer's disease.
    Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
    Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Emelin AIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):25-33. PubMed ID: 18427456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Galantamine (reminyl) in the treatment of severe Alzheimer's disease].
    Gavrilova SI; Kolykhanov IV; Kalyn IaB; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7):57-61. PubMed ID: 19672237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.